Table 4.

Treatment, virus changes and outcomes of patients with COVID-19

	All patients (N = 91)	Local cases (n = 35)	Imported cases (n = 56)	P value
Treatment
Chinese traditional medicine	91 (100.0%)	35 (100.0%)	56 (100.0%)	1.000
Antiviral therapy	89 (97.8%)	33 (94.3%)	56 (100.0%)	0.112
Oxygen therapy	46 (50.5%)	14 (40.0%)	32 (57.1%)	0.306
Intravenous immunoglobulin therapy	22 (24.2%)	5 (14.3%)	17 (30.4%)	0.081
Thymosin alpha1	20 (22.0%)	9 (25.7%)	11 (19.6%)	0.496
Glucocorticoids	13 (14.3%)	3 (8.6%)	10 (17.9%)	0.218
Intravenous antibiotic	12 (13.2%)	2 (5.7%)	10 (17.9%)	0.120
Mechanical ventilation	10 (11.0%)	2 (5.7%)	8 (14.3%)	0.385
Non-invasive (i.e., face mask)	1 (1.1%)	1 (2.9%)	0 (0.0%)	0.145
Invasive	9 (9.9%)	1 (2.9%)	8 (14.3%)	0.385
ECMO	1 (1.1%)	1 (2.9%)	0 (0.0%)	0.145
Hospital stay, days, Median (IQR)	14 (11–18)	14 (11–17)	15 (11–14)	0.403
Duration of SARS-CoV-2 RNA positivity from onset
Nasopharyngeal swabs, days	11 (6–16)	8 (5–16)	12 (8–16)	0.084
Median (IQR), [range]	[1–39]	[1–37]	[4–39]
Feces, days	79/91, 13 (10–19)	29/35, 13 (6–18)	50/56, 13 (10–20)	0.216
Median (IQR), [range]	[1–40]	[1–37]	[4–40]
Duration of SARS-CoV-2 shedding from onset
Nasopharyngeal swabs, days	16 (13–23)	15 (10–22)	17 (14–23)	0.148
Median (IQR), [range]	[6–43]	[8–37]	[6–43]
Feces (days)	79/91, 19 (14–26)	29/35, 18 (11–24)	50/56, 19 (15–27)	0.242
Median (IQR), [range]	[6–43]	[6–37]	[8–43]
Clinical outcome
Discharged	88 (96.7%)	34 (97.1%)	54 (96.4%)	1.000
Died	3 (3.3%)	1 (1.1%)	2 (3.6%)	1.000

Data are n (%) and mean (SD). N is the total number of patients with available data. P values for comparing two groups were derived using Fisher’s exact test for categorized variables and the t-test for continuous variables

COVID-19 Coronavirus disease-2019; SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2; ECMO Extracorporeal membrane oxygenation; NA Not available; SD Standard deviation; IQR Interquartile range